Brief: Akeso Announced That Ivonescimab Granted Priority Review Of NDA By China Nmpa
25/08/2023 13:01
Aug 25 (Reuters) -
* AKESO ANNOUNCED THAT IVONESCIMAB GRANTED PRIORITY REVIEW
OF NDA
BY CHINA NMPA
Source text for Eikon: ID:nPn8rqjd7a
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals